Immunotherapy Success Rate for Head and Neck Cancer: What Patients Need to Know In 2025

What it is:
• Immunotherapy is a type of cancer treatment that helps your own immune system find and attack cancer cells — it works differently from chemotherapy and radiation.

Common drugs used:
• Pembrolizumab (Keytruda) and nivolumab (Opdivo) are checkpoint inhibitors often used in recurrent or metastatic head and neck cancer.

Success rates:
• Response rates — where the tumor shrinks or stabilises — are generally around 15–36% depending on factors like PD-L1 levels, HPV status, and combination with chemotherapy.
• Higher response rates (~23%) are seen when tumors have high PD-L1 expression, and combining immunotherapy with chemo can increase responses (~36%).

Duration matters:
• Even when response rates aren’t very high, the responses can last a long time — many people stay in remission for over a year, and some for years.

Who benefits most:
• HPV-positive cancers often respond better to immunotherapy.
• People whose cancer has returned or spread may get long-term benefit even when other treatments haven’t worked.

Side effects:
• Usually milder than chemotherapy: fatigue, rash, mild inflammation, diarrhea. But it can occasionally affect healthy organs, so early reporting of symptoms is important.

What to talk about with your doctor:
• Ask about your PD-L1 score, HPV status, how immunotherapy might fit with other treatments, and what benefits and side effects you can expect.

💡 Takeaway: Immunotherapy isn’t a cure for everyone — only a portion of people see major shrinkage — but for many, it offers longer life, more durable control of cancer, and often better quality of life than older treatments.

Read more at https://oncodaily.com/oncolibrary/immunotherapy-success-rate-for-head-and-neck-cancer